Metabolic associated fatty liver disease and COVID-19: a double whammy? by Jaime Hui Xian Lin, Veeraraghavan Meyyur Aravamudan

Get full text

Metabolic and Genetic Determinants of Lipid Metabolism Disruption in Non-Alcoholic Fatty Liver Disease by O. Yu. Kytikova, T. P. Novgorodtseva, Yu. K. Denisenko, D. A. Kovalevsky

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Thromboelastography parameters in chronic viral liver disease and liver resection: a retrospective study by Ying Di, Jialu Li, Chunjuan Ye, Zheng Wang, Qianqian Zhu

Subjects: “…chronic viral liver disease…”
Get full text

Intrahepatic Cholestasis in Non-Alcoholic Fatty Liver Disease: Pathogenesis and Role of Ademetionine in Treatment by Ye. N. Shirokova

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus by A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Rare forms of nonalcoholic fatty liver disease: hereditary lysosomal acid lipase deficiency by M. V. Mayevskaya, V. T. Ivashkin, M. S. Zharkova, T. P. Nekrasova, G. I. Ayusheva, R. V. Maslennikov

“…To acquaint general practitioners with a rarely diagnosed disease - the hereditary deficiency of lysosomal acid lipase (DLAL) which can develop under the «mask» non-alcoholic fatty liver disease (NAFLD). Summary. There are two forms of DLAL clinical manifestations: as fulminant lethal Wolman disease and slowly progressing cholesterol ethers storage disease (CESD). …”
Get full text

Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society by V. T. Ivashkin, M. V. Mayevskaya, Ch. S. Pavlov, Yu. P. Sivolap, V. D. Lunkov, M. S. Zharkova, R. V. Maslennikov

“…To present clinical guidelines of the Russian Scientific Liver Society on diagnosis and treatment of alcoholic liver disease to general practitioners. Summary. Harmful alcohol intake is the burning issue for Russia. …”
Get full text

The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease by T. S. Krolevets, M. A. Livzan, S. I. Mozgovoy

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease by Thomas F Baumert, Charlotte Bach, Patrick Pessaux, Catherine Schuster, Frank Jühling, Sarah C Durand, Yujin Hoshida, Fabien Zoulim, Atish Mukherji, Naoto Fujiwara, Marine A Oudot, Armando Andres Roca Suarez, Michel L Tremblay, Barbara Testoni, Joachim Lupberger, Romain Parent, Laurent Mailly, Nassim Dali-Youcef, Emanuele Felli, Maria Saez-Palma, Julien Moehlin, Alessia Virzì, Nicolas Brignon, Eugenie Schaeffer, Romain Martin, Laura Meiss-Heydmann, Zakaria Boulahtouf, Lea Girard, Emma Osswald, Carole Jamey, Daniel Brumaru, Bhuvaneswari Koneru

“…Hepatic PTPRD expression is impaired in aetiologies of chronic liver diseases that are associated with metabolic disease. …”
Get full text

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B by S. N. Batskikh, E. V. Vinnitskaya, E. S. Sbikina, Zh. V. Borunova, A. S. Dorofeev, Yu. G. Sandler

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure by Davide Scalabrini, Paolo Sciuto, Cristina Felicani, Antonia Rudilosso, Pietro Andreone

Get full text

Efficacy of Physiologically Active nutrients in the Treatment of Asthenic Disorders in Patients with Chronic Diffuse Liver Diseases by M. V. Mayevskaya, M. A. Morozova, A. G. Beniashvili, V. D. Lunkov, V. T. Ivashkin

Subjects: “…chronic diffuse liver diseases…”
Get full text

Cholestasis in Chronic Liver Disease and the Role of Ademetionine in its Treatment (Literature Review and Expert Panel Resolution) by K. L. Raikhelson, A. O. Bueverov, E. A. Kondrashina, M. V. Maevskaya, I. B. Khlynov, E. N. Shirokova, V. T. Ivashkin

Subjects: Get full text

Metabolic Profiles of the Gut Microbiota in Patients with Different Stages of Metabolism Dysfunction-Associated Fatty Liver Disease by X. Cao, O. Yu. Zolnikova, R. V. Maslennikov, E. A. Poluektova, E. L. Bueverova, M. S. Reshetova, M. S. Zharkova, V. T. Ivashkin

“…Thus, a decrease in the content of SCFA for patients with MAFLD can be considered as a prognostic marker of an unfavorable course of liver disease.…”
Get full text

The role of non-alcoholic fatty liver disease in the formation of atherosclerotic vascular lesions in patients with abdominal obesity by N. L. Denisov, V. B. Grinevich, Ye. V. Chernetsova, Yu. A. Kravchuk, K. V. Ivashkin

“…Patients’ symptoms, past history, were evaluated to exclude alcoholic or drug-induced liver disease, anthropometric parameters were studied. …”
Get full text

The effect of nuclear transcriptional factor κВ activation inhibitor – curcumine on the experimental immune liver disease by I. N. Alekseyeva, N. V. Makogon, S. I. Pavlovich, T. M. Bryzgina, L. I. Aleksyuk, T. V. Martynova, V. S. Sukhina

Get full text

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study by I. Yu. Pirogova, S. V. Yakovleva, T. V. Neuymina, S. P. Sinitsyn, V. S. Chulkov, T. N. Shamaeva

Subjects: “…nonalcoholic fatty liver disease…”
Get full text

Association of leptin receptor Gln223Arg genetic polymorphism with obesity and non-alcoholic fatty liver disease by A. V. Morozova, N. V. Mal'tseva, Y. A. Gorbatovsky, O. F. Lykova, S. V. Arkhipova

Subjects: Get full text

Association between sleep duration and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis by Kasra Pirahesh, Ali Zarrinnia, Leila Nikniaz, Zeinab Nikniaz

“…Introduction: Considering that both long and short sleep duration may have an association with nonalcoholic fatty liver disease (NAFLD), in this meta-analysis, we analyzed the dose-response association between sleep duration and NAFLD along with meta-analyses of the differences in mean sleep duration between NAFLD patients and healthy controls, and linear meta-analysis of the association between sleep duration and NAFLD. …”
Get full text

Case Report: Cholestatic liver disease in the course of erythropoietic protoporphyria associated with renal hypodysplasia and atrial septal defect by Patryk Lipiński, Agnieszka Lipniacka, Maja Klaudel-Dreszler, Lidia Ziółkowska, Grażyna Kostrzewa, Edyta Odnoczko, Robert Wasilewski, Rafał Płoski, Anna Tylki-Szymańska

“…Progressive cholestatic liver disease (with subsequent congestive heart failure) was observed in the course of EPP. …”
Get full text